Ask AI
SABCS 2025: EBC

CME

Decera Clinical Education Independent Conference Highlights of the San Antonio Breast Cancer Symposium 2025: Early Breast Cancer

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: March 02, 2026

Expiration: September 01, 2026

Activity

Progress
1 2 3
Course Completed

References

  1. Cortes J, Johnston SRD, Martin M, et al. MonarchE: subgroup analysis of adjuvant abemaciclib + endocrine therapy for HR+, HER2-, high-risk early breast cancer by nodal status. Presented at: San Antonio Breast Cancer Symposium 2025; December 19-12, 2025. Abstract PS1-08-08.
  2. Johnston SR, Martin M, O’Shaughnessy J, et al. MonarchE: primary overall survival (OS) results of adjuvant abemaciclib + endocrine therapy (ET) for HR+, HER2-, high-risk early breast cancer (EBC). Presented at: European Society for Medical Oncology Congress 2025; October 17-21, 2025. Abstract LBA13.
  3. Ribociclib [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals; 2025.
  4. Crown J, Stroyakovskii D, Yardley DA, et al. Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival. ESMO Open. 2025;10:[Epub].
  5. Crown J, Stroyakovskii D, Yardley DA, et al. Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR+/HER2− early breast cancer: NATALEE 5-year outcomes. Presented at: European Society for Medical Oncology Congress 2025; October 17-21, 2025. Abstract LBA14.
  6. Hurvitz S, Jarzab M, Ring A, et al. Five-year analysis of distant disease-free survival across key subgroups from the phase 3 NATALEE trial of ribociclib plus a nonsteroidal aromatase inhibitor in patients with HR+/HER2- early breast cancer. Presented at: San Antonio Breast Cancer Symposium 2025; December 19-12, 2025. Abstract PS3-09-08.
  7. Bardia AL, Schmid P, Martin M, et al. Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: results from the global phase III lidERA Breast Cancer trial. Presented at: San Antonio Breast Cancer Symposium 2025; December 19-12, 2025. Abstract GS1-10.
  8. Fulvestrant [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2021.
  9. Elacestrant [prescribing information]. New York, NY: Stemline Therapeutics, Inc.; 2023.
  10. Bellet M, Tolosa P, Hernando C, et al. Elecestrant alone or in combination with triptorelin in premenopausal women with ER+/HER2- early breast cancer: primary analysis from the phase 2 SOLTI-2104-PremiÈRe trial. Presented at: San Antonio Breast Cancer Symposium 2025; December 19-12, 2025. Abstract PD10-01.
  11. Harbeck N, Modi S, Pusztai L, et al. DESTINY-Breast11: neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel + trastuzumab + pertuzumab vs ddAC-THP for high-risk HER2+ early breast cancer. Presented at: European Society for Medical Oncology Congress 2025; October 17-21, 2025. Abstract 291O.
  12. Hoppenworth JE, Yee C, Truman M, et al. Pulmonary toxicities in patients (pts) with metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd): the Mayo Clinic enterprise experience, updated. J Clin Oncology. 2025;43(Suppl 16):1089.
  13. Curigliano G, Harbeck N, Boileau JF, et al. DESTINY-Breast11 safety: neoadjuvant trastuzumab deruxtecan (T-DXd) alone or followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (ddAC-THP) in high-risk, HER2+ early-stage breast cancer. Presented at: San Antonio Breast Cancer Symposium 2025; December 19-12, 2025. Abstract RF6-02.
  14. Pérez-García JM, Cortés J, Ruiz-Borrego M, et al. 3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial. Lancet. 2024;403:1649-1659.
  15. Llombart-Cussac A, Pérez-García JM, Ruiz-Borrego M, et al. Circulating tumor DNA (ctDNA) in HER2+ early breast cancer: a translational analysis of PHERGain. Presented at: San Antonio Breast Cancer Symposium 2025; December 19-12, 2025. Abstract GS1-08.
  16. Piccart-Gebhart M, Holmes E, Baselga J, et al. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial. J Clin Oncol. 2015;34:1034-1042.
  17. Lambertini M, Samy F, Agostinetto E, et al. Adjuvant aromatase inhibitor or tamoxifen in patients with hormone receptor-positive/HER2-positive early breast cancer: an exploratory analysis from the ALTTO (BIG 2-06) trial. Presented at: San Antonio Breast Cancer Symposium 2025; December 19-12, 2025. Abstract GS1-03.
  18. Francis PA, Pagani O, Fleming GF, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med. 2018;12;379:122-137.
  19. Liu Y, Gong Y, Zhu X, et al. Effect of adjuvant carboplatin intensified chemotherapy versus standard of care chemotherapy on survival in women with high-risk early-stage triple-negative breast cancer (CITRINE): a phase 3 randomized trial. Presented at: San Antonio Breast Cancer Symposium 2025; December 19-12, 2025. Abstract RF2-04.
  20. Schmid P, Cortes J, Pusztai L, et al; KEYNOTE-522 Investigators. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382:810-821.
  21. Litton JK, Scoggins ME, Hess KR, et al. Neoadjuvant talazoparib for patients with operable breast cancer with a germline BRCA pathogenic variant. J Clin Oncol. 2020;38:388-394.
  22. Mayer EL, Graham N, Leon-Ferre RA, et al. TBCRC-056: a phase 2 study of neoadjuvant niraparib with dostarlimab for patients with BRCA- or PALB2-mutated breast cancer: results from the TNBC cohorts. Presented at: San Antonio Breast Cancer Symposium 2025; December 19-12, 2025. Abstract RF5-02.
  23. Tung N, Stradella A, Brufsky A, et al. OlympiaN: a phase 2, multicenter, open-label study to assess the efficacy and safety of neoadjuvant olaparib monotherapy and olaparib plus durvalumab in patients with BRCA mutations and early-stage HER2-negative breast cancer. Presented at: San Antonio Breast Cancer Symposium 2025; December 19-12, 2025. Abstract RF5-03.